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Abstract 
Background: Chromosome 14 open reading frame 166 (C14orf166) is upregulated in various tumors, but its role in 
breast cancer has not been reported.
Methods: Quantitative real‑time PCR and western blot were used to determine C14orf166 expression in normal 
breast epithelial cells (NBEC), breast cancer cells, and four matched pairs of breast cancer tissues and adjacent non‑
cancerous tissues. Using immunohistochemistry, we determined C14orf166 expression in paraffin‑embedded tissues 
from 121 breast cancer patients. Statistical analyses were performed to examine the associations among C14or166 
expression, clinicopathological parameters and prognosis outcome of breast cancer. MTT and colony formation assay 
were used to determine the effect of C14orf166 on cell proliferation by overexpression or knockdown of C14orf166 
level.
Results: C14orf166 was upregulated in breast cancer cell lines and tissues compared with the normal cells and 
adjacent normal breast tissues, high C14orf166 expression was positively with advancing clinical stage. The correla‑
tion analysis between C14orf166 expression and clinicopathological characteristics suggested C14orf166 expres‑
sion was significantly correlated with clinical stages, T classification, N classification and PR expression, Kaplan–Meier 
curves with log rank tests showed patients with low C14orf166 expression had better survival, Cox‑regression analysis 
suggested C14orf166 was an unfavorable prognostic factor for breast cancer patients. C14orf166 overexpression pro‑
moted breast cancer cell proliferation, whereas knockdown of C14orf166 inhibited this effect. Further analysis found 
C14orf166 overexpression inhibited cell cycle inhibitors P21 and P27 expression, and increased the levels of Cyclin D1 
and phosphorylation of Rb, suggesting C14orf166 contributed to cell proliferation by regulating G1/S transition.
Conclusion: Our findings suggested C14orf166 could be a novel prognostic biomarker of breast cancer, it also con‑
tributes to cell proliferation by regulating G1/S transition.
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Background
Breast cancer is one of the leading causes of cancer death 
in women worldwide [1]. It is a heterogeneous tumor, 
heterogeneity exists between and within subtypes of 
breast cancer cells [2]. The subtype of breast cancer can 
be divided based on the expression of estrogen recep-
tor (ER), progesterone receptor (PR) and Her2 receptor 
tyrosine kinase (Her2). Thereinto,“triple negative”(ER−/
PR−/Her2−) breast cancer is the most aggressive and 
has poorest prognosis [3]. Some drugs have been used 
to treat breast cancer, for example, Sunitinib [4], Bevaci-
zumab [5] and Trastuzumab [6]. But breast cancer have 
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breast cancer have generated resistance to Trastumab [7]. 
The prevention and treatment are important for breast 
cancer, so it’s essential to find novel prognostic factors 
and targets for breast cancer.
C14orf166 plays critical role in transcription initiation, 
HCV infection, RNA metabolism, and centrosome archi-
tecture. It can interact with PA subunit of influenza virus 
polymerase to activate some genes transcription and 
promote influenza virus replication [8]. Knockdown of 
C14orf166 suppresses the synthesis of about 50  % RNA 
polymerase II transcripts, these suggest C14orf166 regu-
lates gene transcription [9]. Junwei Lee and colleagues 
use proteomics approach find that C14orf166 also inter-
acts with HCVc174 which a mature hepatitis C virus 
core protein, suggesting it may regulate HCV or cellular 
function during HCV infection [10]. C14orf166 interacts 
with DDX1, HSPC117 and FAM98B to form a complex to 
transport RNAs between the nucleus and the cytoplasm, 
suggesting it regulates the fate of RNA [11]. C14orf166 
blocks the phosphorylation of ninein to regulation the 
function of ninein, ninein is required for the centrosome 
maturation, this suggests C14orf166 may participate in 
the centrosome architecture [12, 13].
C14orf166 is overexpressed in many tumors, such as pan-
creatic adenocarcinoma, brain tumor [13] and nasopharyn-
geal carcinoma. In nasopharyngeal carcinoma, C14or166 
is overexpressed in nasopharyngeal carcinoma tissues, its 
expression is significantly correlated with gender, distant 
metastasis, vital status, T classification, N classification 
and clinical stage. It is an unfavorable prognostic factor 
for nasopharyngeal carcinoma patients [14]. In pancreatic 
adenocarcinoma, C14orf166 is overexpressed in the serum 
of patients with pancreatic adenocarcinoma detected by 
surface enhanced laser desorption/ionization time-of-flight 
mass spectrometry (SELDI-TOF–MS), and is a potential 
biomarker for pancreatic adenocarcinoma [15]. But the role 
of C14orf166 in breast cancer hasn’t been studied.
Here, we determined C14orf166 expression in breast 
cancer cells and tissues used quantitative real-time 
PCR and western blot. Then we determined C14orf166 
expression of a cohort of 121 breast cancer patients, and 
examined the relationship between C14orf166 expression 
and clinicopathological characteristic and clinical out-
come. Finally, we determined the effect of C14orf166 on 
cell proliferation by modulating its expression. We found 
C14orf166 not only was a valuable prognostic factor for 
patients with breast cancer, but also promoted breast 
cancer proliferation.
Methods
Human breast cancer tissue specimens
Four fresh breast cancer tissues and their adjacent non-
cancerous breast tissues were obtained from the First 
Affiliated Hospital, Sun Yat-Sen University, China, and 
frozen and stored in liquid nitrogen for further use. A 
cohort of 121 formalin-fixed and paraffin-embedded pri-
mary breast cancer samples also were obtained from the 
First Affiliated Hospital, Sun Yat-Sen University, China, 
from 2001 to 2008. All samples were confirmed by his-
tological and clinical diagnosis. For the use of these clini-
cal samples for research purposes, all samples obtained 
with written informed and approved by the Institutional 
Research Ethics Committee of the First Affiliated Hospi-
tal of Sun Yat-Sen University. The detailed clinical infor-
mation about these samples is shown in Additional file 1: 
Table S1. The clinical stages of all the patients were classi-
fied according to the 2002 TNM staging of UICC (Inter-
national Union against Cancer).
Cell culture and transfection
Normal human breast epithelial cells (NBEC) were cul-
tured in Keratinocyte serum-free medium (Life Technol-
ogies) supplemented with epithelial growth factor, bovine 
pituitary extract. Breast cancer cell lines including MCF-
7, ZR-75-1, T47D, BT549, SKBR3, BT-474, MDA-MB231 
and MDA-MB-361 were purchased from American Type 
Culture Collection and were cultured under conditions 
specified by the manufacturer.
The CDS sequence of C14orf166 was PCR amplified 
from cDNA of NBEC and cloned into the pMSCV-puro 
retroviral vector (indicated as C14orf166), the empty 
vector was used as negative control (indicated as Vec-
tor). Lipofectamine 2000 was used to transfected vectors 
into the indicated cells according to the manufacturer’s 
instruction. The same cells transfected empty vector were 
used as the negative control.
The C14orf166 siRNA (indicated as C14orf166/RNAi) 
and its cognate control siRNA (indicated as Scramble) 
were obtained from Guangzhou RiboBio Co (Guang-
dong, China). 20  nM siRNA were transfected into 
the indicated cells in six plates using Lipofectamine 
RNAiMax Reagent (Life Technologies) according to the 
manufacturer’s instruction.
RNA isolation and quantitative real‑time PCR
Total RNA was extracted using TRIzol reagent (Life 
Technologies), and cDNA was synthesized using Trans-
Script Reverse Transcriptase (TransGen Biotech). 
cDNA products were amplified using CFX-96 Touch 
Real-Time PCR Detection System (BioRad). GAPDH 
were used as an internal control. mRNA levels were 
calculated as 2−[(Ct of C14orf166, Cyclin D1, P21)−(Ct of GAPDH)], 
where Ct represents the threshold cycle of each tran-
script [16]. All experiments were performed in tripli-
cate. The primers selected are as follows: C14orf166: 
forward 5′TGTTCCGACGCAAGTTGA3′ and reverse 
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5′CGCTGCTGTGGATGTTTCT3′.Cyclin D1:forward 
5′-TCCTCTCCAAAATGCCAGAG-3′ and reverse 5′-GG 
CGGATTGGAAATGAACTT-3′. P21:forward 5′-CGAT 
GCCAACCTCCTCAACGA-3′ and reverse 5′-TCGC 
AGACCTCCAGCATCCA-3′. GAPDH:forward 5′GGTG 
GTCTCCTCTGACTTC3′ and reverse 5′CTCTTCCTC 
TTGTGCTCTTG3′.
Western blot and immunohistochemistry (IHC)
Cells were lysed with 50 mM Tris at pH 7.4, 150 mM NaCl, 
1 mM EDTA, 1 % NP-40, 1 % TritonX-100 supplemented 
with protease inhibitors (Complete, Roche). The following 
antibodies were used: anti-C14orf166 (1:500, 19848-1-AP, 
Proteintech), anti-Cyclin D1 (1:1000, sc-753, Santa Cruz 
Biotechnology Inc), anti-P21 (1:500, sc-397, Santa Cruz 
Biotechnology Inc), anti-P27 (1:1000, sc-528, Santa Cruz 
Biotechnology Inc), anti-Rb (ab6075, Abcam) and anti-
phosphorylated Rb (ab47763, Abcam). The membranes 
were stripped and re-probed with an anti-β-actin antibody 
(1:3000, HC201-02, TransGen Biotech) or anti-α-Tubulin 
antibody (1:1000, AT819, Beyotime) as the loading control.
IHC was performed according to standard methods as 
described previously [17]. The following antibodies were 
used: anti-C14orf166 (1:200, 19848-1-AP, Proteintech), 
anti-ER (1:100, ab16660, Abcam) and anti-PR (1:20, 
ab2765, Abcam). The results of staining were scored 
independently by three pathologists blinded to clini-
cal outcome, based on both the proportion of positively 
stained tumors cells and the intensity of staining. The 
proportion of tumor cells was scored as follows: Score 
0—no positive cells, Score 1—up to 10  % positive cells, 
Score 2—10 ~ 50 % positive cells, Score 3—50–80 % posi-
tive cells, Score 4–over 80 % positive cells. The intensity 
of protein expression was shown as follows: 0 (no stain-
ing), 1 (weak staining, light yellow), 2 (moderate staining, 
yellowish brown), and 3 (strong staining, brown).
The staining index (SI) was calculated as the product 
of the staining intensity and the proportion of positive 
cell scores (scored as 0, 1, 2, 3, 4, 6, 8, 9 or 12). Cut-off 
values for C14orf166 expression were chosen based on 
a measurement of heterogeneity using the log-rank test 
with respect to overall survival. The optimal cut-off was 
identified as an SI score of more than or equal to four 
was considered as having high C14orf166 expression, and 
a score less than 4 was considered as having C14orf166 
expression.
Fig. 1 C14orf166 is upregulated in breast cancer cells and tissues. (a, b) Quantitative real‑time PCR and western blot analyzed C14orf166 expression 
in NBEC and breast cancer cells, including MCF‑7, ZR‑75‑1, T47D, BT549, SKBR3, BT‑474, MDA‑MB231 and MDA‑MB‑361. (c, d) Quantitative real‑time 
PCR and western blot analyzed C14orf166 expression in four paired tumor tissues and adjacent normal tissues. Error bars are standard deviation of 
the mean (SD) calculated from three experiments performed in parallel, *p < 0.05
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MTT assay
MTT assay was performed as described previously [18].
Colony formation assay
Colony formation assay was performed as described pre-
viously [19].
Statistical analysis
All statistical analyses were carried out by the SPSS ver-
sion 19.0 software (SPSS, Chicago, IL., USA). The Chi-
square test was used to analyze the correlation between 
C14orf166 expression and clinicopathological charac-
teristics. Bivariate correlations between variables were 
calculated by Pearson’s correlation coefficient. Survival 
curve was plotted using Kaplan–Meier survival analysis 
and compared by the log-rank test. Univariate and mul-
tivariate Cox regression analyses were used to estimate 
the significance of various variables for survival. Results 
are presented as mean ± SD for at least three independ-
ent experiments, cell proliferation assay were tested using 
Student’s t test (two-tailed) for independent samples. 
p < 0.05 in all cases was considered significant.
Results
C14orf166 is upregulated in breast cancer cells and tissues
To investigate the role of C14orf166 in breast cancer, 
we first demonstrated C14orf166 expression in NBEC 
and breast cancer cells. Quantitative real-time PCR and 
western blot assay found C14orf166 expression was sig-
nificantly upregulated in breast cancer cells compared to 
NBEC (Fig. 1a, b). To investigate whether C14orf166 was 
also upregulated in breast cancer tissues, we determined 
C14orf166 expression in four paired tumor tissues (T) 
and matched adjacent normal tissues (ANT), quantitative 
real-time PCR and western blot assay showed C14orf166 
also was upregulated in breast cancer tissues compared 
to adjacent noncancerous tissues (Fig. 1c, d).
C14orf166 overexpression is associated with clinical 
progression of breast cancer
We used IHC to determine C14orf166 expression in 
121 paraffin-embedded, archival breast cancer tissues, 
including 15 stageI tumors, 55 stage II tumors, 34 stage 
III tumors, 17 stage IV tumors. C14orf166 was high 
expression in 63 (52.1 %) cases, and no or low expression 
in the remaining 58 (47.9  %) cases (Table  1). The posi-
tive rate increased with advancing clinical stage as fol-
lows: 13.3 % for stage I (2/15), 43.6 % for stage II (24/55), 
67.6  % for stage III (23/34), 82.4  % for stage IV (14/17) 
(Table 1). IHC assay shown that C14orf166 was primarily 
localized in the tumor cell nuclei (Fig. 2), and its expres-
sion was positively correlated with advancing clinical 
stage (Fig.  2), Taken together, these results suggested 
C14orf166 expression increased with advancing clinical 
stage in breast cancer.
We examined the relationship between C14orf166 
expression and clinicopathological characteristics using 
Chi-square test, As presented in Table  2, we revealed 
that high C14orf166 expression was significantly cor-
related with advanced clinical stage (p  <  0.001), T clas-
sification (larger tumor size, p  <  0.01), N classification 
(lymph node involvement, p  <  0.001), M classification 
Table 1 Correlation between  C14orf166 expression 











 <40 27 12 15 0.424
 ≥40 94 46 48
Clinical stage
 I 15 13 2 <0.001
 II 55 31 24
 III 34 11 23
 IV 17 3 14
T classification
 T1 26 17 9 <0.01
 T2 65 34 31
 T3 23 6 17
 T4 7 1 6
N classification
 0 45 33 21 <0.001
 1 48 18 30
 2 25 6 19
 3 3 1 2
M classification
 Yes 6 0 6 0.018
 No 115 58 57
ER
 0 51 23 28 0.325
 1 58 28 30
 2 9 4 5
 3 3 3 0
PR
 0 49 18 31 0.02
 1 60 30 30
 2 10 9 1
 3 1 0 1
 4 1 1 0
Vital status (at follow‑up)
 Alive 64 51 13 <0.001
 Dead 57 7 50
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(distant metastasis, p =  0.018), PR (p =  0.02) and vital 
status (p  <  0.001). But there were no statistically corre-
lations between C14orf166 expression and age and ER. 
The correlations between C14orf166 and the clinico-
pathological characteristics were further confirmed used 
Spearman’s correlation analysis, as shown in Table  2, 
C14orf166 expression were significantly correlated with 
survival time (p < 0.001), vital status (p < 0.001), advanc-
ing clinical stage (p < 0.001), T classification (p = 0.001), 
N classification (p  <  0.001) and PR (p  =  0.009). There 
weren’t significance correlations between C14orf166 
expression and age and ER. But distant metastasis which 
significantly correlated with C14orf166 expression used 
Chi-square test had not significance correlation with 
C14orf166 expression used Spearman’s correlation analy-
sis. These results suggested C14orf166 expression was 
positively correlated with and advanced clinical stage, T 
classification, N classification, PR and vital status.
C14orf166 is a poor prognostic factor for patients 
with breast cancer
Kaplan–Meier survival analysis and the log-rank test 
demonstrated that the overall survival of the patients with 
high C14orf166 expression was significantly shorter than 
those with low C14orf166 expression (Fig. 3a). Univariate 
Cox regression analysis showed that C14orf166 expres-
sion (p < 0.001), clinical stage (p = 0.013), T classification 
(p < 0.001) and N classification (p = 0.007) were unfavora-
ble prognostic factors (Table  3). To determine whether 
C14orf166 expression is an independent prognostic fac-
tor of outcomes, multivariate survival analysis revealed 
C14orf166 expression, clinical stage, T classification and 
N classification were recognized as independent prognos-
tic factors for patients with breast cancer (Table 3).
Additionally, we analyzed the prognostic value of 
C14orf166 expression in selective subgroups of breast 
cancer patients stratified according to clinical stage. 
Patients with tumors exhibiting high C14orf166 expres-
sion had significantly shorter overall survival than those 
with low C14orf166 expression in the clinical stage I–
II subgroup (Fig.  3b, p  <  0.05) and clinical stage III–IV 
subgroup (Fig. 3c, p < 0.05). These suggested C14orf166 
was a valuable prognostic factor for patients with breast 
cancer.
C14orf166 contributes to cell proliferation of breast cancer
To explore the role of C14orf166 in the progression 
of breast cancer cells, we overexpressed C14or166 in 
breast cancer cells ZR-75-1 and MDA-MB361 to deter-
mine its effect on cell proliferation, MTT analysis found 
C14orf166 overexpression increased proliferation rate 
of breast cancer cells (Fig.  4a), colony formation assay 
Fig. 2 C14orf166 expression in breast cancer tissues from patients at different clinical stages. Representative images of C14orf166 expression in 
breast cancer tissues at different clinical stages determined by IHC
Table 2 Spearman analysis of  correlation between   
C14orf166 and clinicopathological characteristics
Variables C14orf166 expression level
Spearman correlation p Value
Survival time −0.735 <0.001




Clinical stage 0.404 <0.001
T classification 0.295 0.001
N classification 0.390 <0.001
M classification 0.088 0.270
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suggested C14orf166 overexpression significantly pro-
moted proliferation of breast cancer cells (Fig.  4b). To 
further examined the effect of C14orff166 on cell prolif-
eration, we downregulated C14orf166 used small infer-
ence RNA (siRNA), MTT analysis found knockdown of 
C14orf166 reduced proliferation rate of breast cancer 
cells (Fig.  4a), colony formation assay confirmed that 
C14orf166 knockdown significantly inhibited prolifera-
tion of breast cancer cells (Fig. 4b). Taken together, these 
results suggested C14orf166 regulated the proliferation 
of breast cancer cells.
Cell proliferation is regulated by many key cell cycle 
regulatory proteins, including P21, P27, Cyclin D1, Rb 
and the phosphorylation level of Rb. These proteins play 
critical role in G1/S transition. We investigated their lev-
els by modulating C14orf166 expression. Quantitative 
real-time PCR assay found when C14orf166 was over-
expressed in indicated breast cancer cells, P21 and P27 
Fig. 3 The relationship between C14orf166 expression and clinical outcome. a Kaplan–Meier overall survival curves for the patients with high 
versus low C14orf166 expression. b Kaplan–Meier overall survival curves for the patients at clinical stage I–II with high versus low C14orf166 expres‑
sion. c Kaplan–Meier overall survival curves for the patients at clinical stage III–IV with high versus low C14orf166 expression
Table 3 Univariate and multivariate analyses of various prognostic parameters in patients with liver cancer Cox-regres-
sion analysis
Univariate analysis Multivariate analysis
No. patients p Regression coefficient
(SE)
p Relative risk 95 % Confidence 
interval
C14orf166 <0.001 2.678 (0.412) <0.001 15.231 6.472–35.847
 Low expression 58
 High expression 63
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were upregulated, when C14orf166 was downregulated, 
P12 and P27 were downregulated (Fig. 5a). Western blot 
showed that Cyclin D1 and the phosphorylation level 
of Rb were decreased, P21 and P27 were increased, Rb 
was not changed, when C14orf166 was overexpressed. 
Cyclin D1 and the phosphorylation level of Rb were 
increased, P21 and P27 were decreased, when C14orf166 
was downregulated (Fig. 5b). These suggested C14orf166 
promoted cell proliferation by accelerating G1/S transi-
tion. We have found C14orf166 expression was corre-
lated with T classification, the results investigated from 
breast cancer cells also found C14orf166 promoted 
cell proliferation. Results from clinic and cells were 
consistent.
Fig. 4 C14orf166 contributes to the proliferation of breast cancer. a MTT assay investigated the role of C14orf166 expression in cell proliferation by 
modulating its expression in breast cancer cells ZR‑75‑1 and MDA‑MB‑361. b Colony formation assay determined the role of C14orf166 expression 
in cell proliferation. Representative micrographs (left) and quantification (right) of crystal violent stained cell colonies. Error bars are standard devia‑
tion of the mean (SD) calculated from three experiments performed in parallel, *p < 0.05
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Discussion
In our current studies, we revealed C14orf166 was over-
expressed in breast cancer cells and tissues, it might be a 
novel oncogene, we further analyzed C14orf166 expres-
sion in a cohort of 121 samples by IHC, and investi-
gated the correlation between C14orf166 expression 
and clinicopathological characteristics. Statistical analy-
ses suggested C14orf166 expression was increased with 
advancing clinical stage, and had significance correlation 
with advanced clinical stage, T classification, N classifi-
cation, PR and vital status. Patients with high C14orf166 
expression had shorter survival than those with low 
C14orf166 expression. C14orf166 could serve as a valu-
able prognostic factor. We also determined the role of 
C14orf166 in cellular proliferation, and found overex-
pression of C14orf166 promoted cellular proliferation, 
knockdown of C14orf166 inhibited cellular proliferation. 
Mechanism analysis revealed C14orf166 promoted cell 
proliferation by accelerating G1/S transition.
Centrosomal protein ninein interacts with glycogen 
synthase kinase 3beta (GSK-3β), and be phosphorylated 
by GSK-3β [20]. The activity of Janus kinase 2 (JAK2) is 
inhibited by ninein [21], constitutive activation of JAK2/
STAT5 promotes resistance to apoptosis and contrib-
utes to tumorigenesis of breast cancer [22], these suggest 
ninein may inhibit the development and progression of 
breast cancer. C14orf166 interacts with ninein to block 
the phosphorylation of ninein catalyzed by GSK-3β 
[13], suggesting C14orf166 may inhibit ninein, and acti-
vate JAK2 to promote breast cancer progression, but 
this speculation remain to be confirmation. The regu-
lation mechanism of C14orf166 is still to be explored. 
JAK2/STAT3 promotes self-renewal of breast cancer 
stem cells, CD24−CD44+ is a marker for breast cancer 
stem cells [23, 24]. Activation of JAK2/STAT3 pathway 
preferentially promotes the self-renewal of C24−CD44+ 
breast cancer stem cells [25]. It reveals that C14orf166 
may promote self-renewal of breast cancer stem cells.
Yazhou Cui et, al. find C14orf166 is higher expression 
in pancreatic cancer with lymph node metastasis than 
that of in pancreatic cancer without lymph node metas-
tasis by difference gel electrophoresis, they speculate 
C14orf166 could be a novel metastasis-associated pro-
tein [26]. In our study, we found there was a correlation 
between C14orf166 expression and lymph node metas-
tasis, it was aggressed with previous report. But there 
wasn’t a correlation between C14orf166 expression and 
distant metastasis. The different results may cause by dif-
ferent kinds of tumors. However, our findings still need 
to be replicated, and further investigation used more 
patients’ tissues is required to verify these hypotheses.
Conclusions
In summary, our research show that C14orf166 is an 
unfavorable prognostic factor for breast cancer patients, 
patients with high C14orf166 expression have shorter 
survival than those with low C14orf166 expression. 
C14orf166 accelerates G1/S transition and promotes pro-
liferation of breast cancer cell.
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